BioCentury
ARTICLE | Clinical News

LJPC-501: SPA received

March 9, 2015 7:00 AM UTC

La Jolla said it received an SPA from FDA for a double-blind, placebo-controlled, U.S. Phase III trial of LJPC-501 in about 315 patients. La Jolla plans to begin the trial this quarter. ...